Voyager Life PLC - Acquisition of Amphora Health
Announcement provided by
Mendell Helium plc · MDH30/01/2024 07:00
30 January 2024
Voyager Life plc
("Voyager" or the "Company")
Acquisition of Amphora Health
Voyager, the health and wellness group formulating, manufacturing and supplying high-quality Cannabidiol (CBD), hemp seed oil and hemp-related products, is pleased to announce that it has acquired Amphora Health Ltd ("Amphora"), owner of the Amphora and Infused Amphora brands which comprise a range of CBD oils, vapour products and accessories.
The consideration payable for Amphora will be satisfied through the issue of 416,666 new ordinary shares of
Completion of the acquisition is expected to take place by 29 February 2024 at the time of the transfer of shares in Amphora to Voyager. A further announcement will be made in due course.
About Amphora
Infused Amphora is a British CBD wellness brand founded in 2020 by Canadian industry experts to support people in reaching their wellness goals through the power of the hemp plant. The entire collection of its premium products are all natural, THC free and designed to help with a variety of everyday conditions. The company has 23 ingestible CBD products validated on the FSA's novel foods list.
Importantly, given forthcoming changes in
Amphora achieved sales in the year to 31 July 2022 (its last accounts date) of approximately
The operations of Amphora will be moved to Voyager's existing premises and management are therefore not expecting any increase in overheads at this time. No members of the Amphora team will be employed by Voyager and none of the premises or storage facilities occupied by Amphora are included in the acquisition.
Nick Tulloch, Chief Executive Officer and Founder of Voyager, said: "We are delighted to be adding into the Voyager group the well respected Amphora brands. A 4.7 (excellent) rating on Trustpilot is testament to the quality of the products. This acquisition achieves two objectives for us. Importantly, it provides us with 23 products validated on the FSA's novel foods list, thereby further opening up the
"In both cases, we will aim to bring manufacturing of Amphora products into our VoyagerCann manufacturing facility, thereby lowering the cost of production and enhancing margins.
"It is also important to note, as has been the case with many of our operations, this acquisition has been achieved at very low cost. Several of our competitors have spent considerable sums on novel foods compliance and product development. The opportunity to combine Amphora's business with ours at a modest price is expected to be beneficial for all shareholders."
This announcement contains inside information for the purposes of the
ENDS
Enquiries:
Voyager Life plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti/Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
Stanford Capital Partners LLP (Broker)
Patrick Claridge
Bob Pountney |
+44 (0) 203 3650 3650
+44 (0) 203 3650 3651 |
Notes to Editors:
About Voyager
Voyager was founded in 2020 and is based in
The Company's philosophy of plant-based health and wellness is embodied in its mission statement and hashtag of "Choose you". With an experienced team and a product line created in line with the
Through Voyager's bespoke skincare product creation and development division, voyagerCann, the Company also offers a full turnkey service to other CBD, skincare and cosmetics brands assisting them in developing and launching new products with a manufacturing and distribution facility in
Website and social media links:
Voyager:
https://www.instagram.com/voyagercbd/
https://twitter.com/voyagercbd
https://www.linkedin.com/company/voyager-cbd/
https://www.facebook.com/voyagercbd/
voyagerCann:
https://www.instagram.com/voyagercann/
https://twitter.com/voyagercann/
https://www.linkedin.com/company/voyagercann/
https://www.facebook.com/voyagercann/
Amphora:
https://www.infusedamphora.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.